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Trio-based whole-exome sequence (WES) data have established confident genetic diagnoses in40% of previously undiagnosed individ-
uals recruited to the Deciphering Developmental Disorders (DDD) study. Here we aim to use the breadth of phenotypic information re-
corded in DDD to augment diagnosis and disease variant discovery in probands.Median Euclidean distances (mEuD) were employed as a
simple measure of similarity of quantitative phenotypic data within sets ofR10 individuals with plausibly causative de novomutations
(DNM) in 28 different developmental disorder genes. 13/28 (46.4%) showed significant similarity for growth or developmental mile-
stone metrics, 10/28 (35.7%) showed similarity in HPO term usage, and 12/28 (43%) showed no phenotypic similarity. Pairwise com-
parisons of individuals with high-impact inherited variants to the 32 individuals with causative DNM in ANKRD11 using only growth
z-scores highlighted 5 likely causative inherited variants and two unrecognized DNM resulting in an 18% diagnostic uplift for this gene.
Using an independent approach, naive Bayes classification of growth and developmental data produced reasonably discriminative
models for the 24 DNM genes with sufficiently complete data. An unsupervised naive Bayes classification of 6,993 probands with
WES data and sufficient phenotypic information defined 23 in silico syndromes (ISSs) and was used to test a ‘‘phenotype first’’ approach
to the discovery of causative genotypes using WES variants strictly filtered on allele frequency, mutation consequence, and evidence of
constraint in humans. This highlighted heterozygous de novo nonsynonymous variants in SPTBN2 as causative in three DDD probands.Introduction
The clinical phenotype in a single individual has remark-
able power to predict the detection of a specific causative
ultra-rare genotype, well illustrated by dysmorphic syn-
drome diagnoses such as Down syndrome (MIM:
190685), Williams-Beuren syndrome (MIM: 194050), and
Cornelia de Lange syndrome (MIM: 122470). Such diagno-
ses are based on a clinically recognizable pattern of phys-
ical and behavioral characteristics, most notably pre- and
post-natal growth, facial appearance, neurodevelopmental
trajectory, and specific sets of malformations. The molecu-
lar pathologies associated with these syndromes have
shown high levels of mechanistic convergence, particu-
larly when phenotypic similarities between different syn-
dromes are considered. These groups of syndromes (often
described as lumped)—RASopathies (e,g., Noonan syn-
drome,1 Costello syndrome, neurofibromatosis type 12),
cohesinopathies (e.g., Cornelia de Lange syndrome,3 Rob-
erts syndrome4), ciliopathies (e.g., Bardet Biedl Syndrome,
Joubert syndrome),5 and others—predict biological relat-
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phenotypic patterns seen in human developmental disor-
ders of interest to basic scientists as well as diagnosticians.
The Deciphering Developmental Disorders (DDD) study
aims to develop and use statistically robust, clinically
applicable computational genomic approaches to achieve
a definite genetic diagnosis within the cohort of >13,000
affected individuals with developmental disorders.6,7
DDD inclusion criteria specifically targeted individuals in
whom a clinical diagnosis could not be made and basic ge-
netic investigations were normal.8 To date, 40% of the
DDD probands have a confident diagnosis established us-
ing trio-based exome sequencing9 most commonly due
to a de novo mutation (DNM) affecting the coding region
of a single developmentally critical gene. Indeed, the iden-
tification of a disruptive DNM in a gene in which monoal-
lelic variants are known to cause developmental disease
has, without any reference to the associated phenotype, a
positive predictive diagnostic value of >75%.9 Unsurpris-
ingly, there is marked locus heterogeneity associated with
developmental disorders with no individual locus account-
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remain undiscovered. With sufficient scale and computa-
tional power, it is likely that all of these new loci will be
discovered using human genetics data alone in the next
few years.
Given the strong track record of clinically delineated
phenotypic patterns in diagnostic analysis and gene dis-
covery research, we hypothesized that a computational
approach to phenotypically driven partitioning of the
cohort will increase the power of human genetic analysis
to detect loci haboring causative variants and to elucidate
the underlyingmolecular mechanisms. In this study we as-
sessed the utility of computational analysis of phenotypic
data for both genetic diagnosis and gene discovery using a
large cohort of probands with severe developmental disor-
ders and trio whole-exome sequencing (WES) data. We
used median Euclidean distance as a simple measure of
similarity, and naive Bayes probabilistic methods, inde-
pendently, to discover phenotypic patterns, which we
have termed in silico syndromes (ISSs). Such models have
predictive potential in ranking different plausible variants
in an individual and in phenotype-first approaches to gene
discovery.Material and Methods
The quantitative data considered here included measures of
growth (proband height, weight, occipital-frontal circumference,
and gestation) and of development (proband age for walking inde-
pendently, sitting independently, uttering first words, and ex-
pressing a social smile). Growth data were expressed as z-scores
with respect to population norms following the LMS methodol-
ogy.10 In addition, we considered categorical data on phenotypic
sex and the set of human phenotype ontology (HPO) terms that
report clinical observations. To these data we applied a number
of distance measures to quantify the similarity, or otherwise, of
sets of probands sharing a genetic diagnosis. We then adopted
naive Bayes classification as a means of learning probabilistic
models from the data, initially following a supervised approach
and then learning the models in an unsupervised fashion. These
results were assessed using existing tests of classification accuracy
and overrepresentation as follows.
Distance Measures from Quantitative Data and HPO
Terms
A summarymeasure of the distance betweenmembers a set of pro-
bands based on their growth data was calculated as the median
Euclidean distance (mEuD) in all pairwise comparisons of growth
z-scores between probands in the set. Development data were
treated similarly. A summary measure of distance based on pro-
band HPO annotations was calculated as the mean of the
maximum information (log probability of the most informative
[parent] HPO term) in all pairwise comparisons between probands
in the set. In this case, summary statistics were derived from a ma-
trix of all pairwise distance values, rescaled to increase from 0 by
subtracting the overall maximum information value. For growth,
development, and HPO data, median (or mean) distances for
selected genes were assessed with regard to a distribution of dis-
tances for 100,000 random sets of probands of the same size by
z-score.934 The American Journal of Human Genetics 105, 933–946, NovemNaive Bayes Classification
Naive Bayes classifiers combine the a priori probability of a pro-
band belonging to a category with the probabilities of phenotypic
attributes being ‘‘low,’’ ‘‘mid,’’ or ‘‘high’’ (in the multinomial case)
conditional on the sample belonging to the specified category.11
The naive Bayes approach assumes that attributes are condition-
ally independent and hence the conditional densities can be
calculated more easily. Having obtained the probability tables
from the observed data, the most probable classification for an
observation (maximum a posteriori) can be obtained by Bayes
rule. The use ofmultinomial probability tables requires the pheno-
typic data to be discretized into a set number of bins. We achieved
this by maximizing entropy, that is, by approximately equalizing
the number of samples per bin.
The classification error rate of the naive Bayes classifier was
calculated by the 0.632 bootstrap method:
ð1 0:632Þ  resubstitution-error þ 0:632  bootstrap-error
where the resubstitution-error was12 calculated after training on the
entire dataset and the bootstrap-error from 1,000 bootstraps where
the data were resampled with replacement to obtain a new
training set and accuracy on samples not in the resampled set
was evaluated. These measures of error underestimate and overes-
timate the true error rate, respectively, and their combination bet-
ter reflects the true rate.Unsupervised Naive Bayes Clustering
Naive Bayes approach for unsupervised clustering was performed
using phenotype data from the whole cohort. To enable classes
to be learned—rather than being specified as above—we adapted
a maximum likelihood algorithm13,14 capable of simultaneously
assigning labels and calculating probability tables for a given num-
ber of classes (k), then selected the optimal value of k by exploring
values from 2 to 30 (as we found the trade-off between model
complexity and fit to the data to lie below 30). A generalization
of the calculation of probabilities in naive Bayes models allows
optimal (maximum likelihood) models to be computed for unla-
beled samples.13,14 As for supervised naive Bayes models, we are
able to inspect the probability tables that make up the model
and to calculate model fitting measures such as AIC when
exploring alternative values for the number of categories, k. In un-
supervised clustering, only the number of categories k is initially
specified and all probabilities are calculated through an iterative
procedure to generate an unsupervised clustering of the data. For
values of k from 2 to 30 (range dependent on the number of
data points), we ran the parameter optimization procedure from
random starting values 1,000 times and repeated this process 3
times. The best parameter values for each value of k and the best
choice of k were found by minimizing AIC. We refer to these clus-
ters as in silico syndromes (ISSs). The clustering algorithms were
implemented in R and in Java by the authors, following
Collins.14 The code developed for our analysis is provided in the
ISS online repository (see Web Resources).
Of note, conditional probabilities can be calculated in the case
of missing values. In contrast, t-SNE clustering was performed
on the numerical data directly, but samples with missing values
could not be considered and duplicate samples had to be removed.Tests for Similarity of HPO Terms
The similarity of a set of probands defined by an ISS was assessed
through the HPO terms assigned to each proband using theber 7, 2019
Figure 1. Summary of the Phenotypic Data from DDD Employed in This Study
(A) Description of categorical data types used in the analyses described in the Results.
(B) Description of quantitative data described in the Results.
(C) Overview of the type and purpose of the analyses described in the Results.
6,993 of the first 7,833 probands from the DDD 8K trio exome data freeze had sufficient phenotypic data available to be used for the
median Euclidean distance analysis and the naive Bayes classification approaches. The results of these analysis were gene models and
in silico syndromes that were then used for analysis of strictly filtered inherited variants and a phenotype first approach to gene enrich-
ment for the purposed of novel locus and/or mechanisms discovery.hpo_similarity tools11 (see Web Resources) following the method
developed for diagnostic DNMs. This method computes, for a set
of probands, themaximum information content pairwise between
probands and compares these values to those of a null distribution
of values from random sets of the same size.
Tests for Overrepresentation and Significance
Fisher’s exact test was used to determine whether an ISS was over-
represented in alternative categorizations of probands (1) by mal-
formation category (a set of high-level HPO terms) and (2) by
DNM. The resulting p values were adjusted for the number of
ISSs tested (the threshold for significance was 0.05). In Manhattan
plots, the level of genome-wide significance was set by the Bonfer-
roni method: 0.05/(number of ISS * number of genes tested).Results
Collection, Characteristics, and Completeness of DDD
Phenotypic Data
Throughout the DDD study (during the recruitment period
and subsequently), phenotypic information on each re-
cruited proband was entered and/or updated using a
custom, secure on-line system within DECIPHER (see
Web Resources) by designated professionals at referring
centers and authorized by the clinician who had examined
the affected individual.
The categorical phenotypic information used in this
study consisted of phenotypic sex and the set of human
phenotype ontology terms used to describe the clinical is-
sues (Figure 1A). The quantitative data used for analysis
consisted of growth data expressed as z-scores and develop-
mental data expressed as proband age (in months) forThe Americanwalking independently, sitting independently, uttering
first words, and expressing a social smile (Figure 1B).
Analysis of the DDD data is ongoing and the data used
here are derived from the first 7,833 probands that have
trio WES data available, of which 6,993 probands had suf-
ficient phenotypic data for analysis (Figure 1C).Median Euclidean Distance (mEuD) as a Measure of
Similarity in DDD Phenotypic Data
To determine whether there is discriminative value in
aggregated phenotypic parameters for specific loci in
which variants have been confidently associated with dis-
ease, we used the median of the pairwise Euclidean
distances between all individuals with likely causative
de novo variants in a specific gene. The observed mEuD
was compared to an expected level derived from multiple
random sampling of sets of the same size from the whole
group. mEuD is agnostic to the direction or degree of devi-
ation of the phenotypic parameter and only reflects the
level of similarity within a set; so, for example, two genes
with very similar growth mEuD scores may comprise sets
of affected individuals with extremely different growth pa-
rameters between the genes.
There were 28 genes in which R10 individuals had re-
ported DNM and complete growth data (birth weight,
gestation, postnatal height, weight, and head circumfer-
ence). mEuD for growth and development and a previ-
ously described15 distance measure for HPO terms were
calculated for each group and compared to a random sam-
pling of groups of the same data in identically sized groups
from the DDD data (Figure 2A, Table 1). This showed thatJournal of Human Genetics 105, 933–946, November 7, 2019 935
Figure 2. Phenotype-Based Categorization of Individuals with Likely Causative De Novo Mutations in Confirmed Developmental
Disorder Genes
(A) Histograms showing the distribution of median distances of random sets of DDD probands for growth (purple), similarity of Human
Phenotype Ontology term attributions (brown), and developmental milestone metrics (turquoise). In the upper panel the striking sim-
ilarities observed in median distances within the group of individuals with de novomutations (DNM) in ANKRD11 are indicated by the
red line. In the lower panel the median distances for the individuals with DNM in DYNC1H1 are indicated by the red lines, which shows
no obvious similarity within this group.
(B) Histogram showing the distribution of pairwise Euclidean distances for growthmetrics for the individuals with ANKRD11DNM (pur-
ple). The red arrows representing the median of the pairwise comparisons of the individuals with high-impact inherited variants in
ANKRD11 with the DNM individuals. The green line represents the mEuD of all DDD probands against the ANKRD11 DNM case
subjects.
(C) Boxplot showing the distribution of pairwise distances of individuals with inherited variants and DNM in ANKRD11, ARID1B, and
KMT2A (dark purple). For comparison the distribution of distances between the individuals with DNM and all other DDD probands is
shown (light purple).
(D) The naive Bayes model for each of the 24 DNM genes with sufficient data is summarized by the discretized values in ten phenotypic
categories. Cell shading indicates the discretized value where the value has a probability>0.5 (0.6 for binary variables). A key is provided
describing the discrete groupings. These models were based on the observed phenotypes for each gene in isolation but generated appar-
ently discriminative patterns.
(E) To explore the diagnostic potential of the 24 gene models shown in (D), a confusion matrix was created showing the assignments
based on each gene model using only phenotypic data from all individuals with diagnostic DNM assignments (columns). The diagonal
represents the concordance of the phenotypic and genetic assignment.
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Table 1. Similarity between Individuals with Likely Causative De Novo Variants in 28 Different Genes
Gene
Growth Development HPO (Mean of Max IC)
p Value z-Score p Value z-Score p Value z-Score
KMT2A 0.0058* 2.3523 0.1854 0.7322 0.0000* 4.3303
ARID1B 0.0091* 2.1949 0.1600 0.8220 0.0000* 4.3420
ANKRD11 0.0004* 2.9911 0.0074* 1.2472 0.0000* 4.9775
DDX3X 0.0132* 2.0547 0.1875 0.7794 0.0939 1.3331
DYRK1A 0.0098* 2.1117 – – 0.0000* 4.5538
ADNP 0.1497 1.0288 – – 0.0668 1.5174
MED13L 0.0200* 1.8917 0.8971 1.0019 0.0132* 2.2639
EP300 0.1282 1.1087 – – 0.0001* 3.7941
SATB2 0.0016* 2.5532 – – 0.0000* 3.9988
MECP2 0.1429 1.0485 – – 0.5124 0.0511
DYNC1H1 0.8245 0.9138 0.9580 2.0714 0.0200* 2.1047
PURA 0.1306 1.0952 – – 0.5964 0.2668
CTNNB1 0.4570 0.1706 – – 0.2412 0.6985
ASXL3 0.0068* 2.1506 – – 0.8509 1.0434
SYNGAP1 0.0013* 2.5082 0.3651 0.4461 0.8891 1.2212
SCN2A 0.5408 0.0357 – – 0.1092 1.2397
POGZ 0.1678 0.9488 – – 0.4933 0.0021
CDK13 0.0032* 2.3295 – – 0.0316* 1.9063
STXBP1 0.4528 0.1809 – – 0.0702 1.5038
SETD5 0.0009* 2.5731 – – 0.5510 0.1525
EHMT1 0.0162* 1.8967 – – 0.5816 0.2266
TCF20 0.2386 0.7364 – – 0.0495* 1.6879
PTPN11 0.0689 1.3813 – – 0.0008* 3.2996
PPP2R5D 0.2137 0.8091 – – 0.0020* 3.0120
KAT6A 0.3261 0.5026 – – 0.3382 0.4030
FOXP1 0.1304 1.0885 – – 0.0624 1.5660
CREBBP 0.3879 0.3471 – – 0.0063* 2.5684
CASK 0.3241 0.5091 – – 0.2016 0.8301
Asterisk (*) indicates significant p values (%0.05).16 of the 28 gene groups showed evidence of similarity; 12
for growth, 10 for HPO (6 overlap with growth) significant
at p < 0.05 after Benjamini Hochberg correction, and 1 for
development nominally significant at p < 0.05 (overlaps
growth and HPO). The group of individuals with DNM in
ANKRD11 was exceptional, showing striking levels of sim-
ilarity for all three parameters (Figure 2A, top) whereas
other loci, such as DYNC1H1, showed no significant simi-
larity in any phenotypic domain (Figure 2A, bottom).
The distribution of the mEuD in the randomly selected
sets fromDDDprobands is normally distributed for growth
but significantly skewed for development. A z-score could
thus be calculated from the growth data which gives direc-
tionality to any significant deviation from the expectedThe Americanthe mEuD (Table 1). In all 12 gene sets with p < 0.05, the
z-score for growth metrics was negative indicating that
the groups were more similar than would be expected by
chance.
Classifying Inherited Variants using mEuD Growth
Models from DNM
To explore the wider diagnostic utility of the mEuD gene-
growth models derived from individuals with de novo,
likely causative variants, we examined the pairwise
Euclidean distances of individuals with inherited variants
in the cognate genes. The variants used for analysis were
strictly filtered on allele frequency, evolutionary conserva-
tion, and predicted consequence to enrich for high impactJournal of Human Genetics 105, 933–946, November 7, 2019 937
variants (see Material and Methods; Figures 2B and 2C).
Three genes (ANKRD11, ARID1B, and KMT2A) were chosen
for study for the following reasons: they are common
causes of developmental disorders (each accounting for
>0.5% DNM diagnoses in our dataset), each have distinc-
tive clinical features, each shows significant mEuD growth
similarity, and there were R6 high-impact inherited vari-
ants in probands from the 6,993 DDD trio WES data.
The seven individuals with apparently inherited hetero-
zygous high-impact variants in ANKRD11 and adequate
phenotype data appeared to have a growth pattern that
is more similar to ANKRD11DNM cases than that expected
based on a comparison using the whole cohort (Figures 2B
and 2C). In support of these being causative variants, the
HPO term distances between each of these probands
and the 32 de novo ANKRD11 case subjects were lower
than would be expected by chance in six case subjects
(p < 0.05; Figure S1). The clinical and genetic information
on these individuals was then reviewed and is summarized
in Table 2. Individual (258544) was referred to the project
with a clinical diagnosis of KBG syndrome made prior to
recruitment into DDD. This individual and another
(265784) were subsequently shown to have variants that
had occurred de novo—these had been previously misas-
signed due to poor coverage in one or both of the parental
exomes. For 265784, the growth was similar (p value
0.0004) but the HPO term usage was not (p value 0.09)
whereas 258544 was similar to other individuals with
ANKRD11 DNM for both growth and HPO term usage
(p values of 0.04 and 0.003, respectively). Clinic reap-
praisal of the seven probands (referring clinicians and/
or DRF and HVF) concluded that six had features consis-
tent with their ANKRD11 genotype with the remaining
case subject being considered only possibly consistent
(301622).
In contrast, the growth pattern of individuals with
ARID1B apparently inherited high-impact variants were
less similar to the individuals with ARID1B DNM than the
whole cohort. One of these six had a clinical diagnosis of
Coffin Siris syndrome at recruitment and review of the
trio WES data following our analysis confirmed that this
mutation has occurred de novo. In this individual the HPO
term similarity was highly significant (z-score 5.3) but
the growth mEuD somewhat dissimilar (z-score 0.99)
from individuals with DNM (Figure S1). None of the
other five individuals showed significant HPO term
similarity and only one had significant growth similarity
to the known ARID1B DNM (DDDP120820 z-score 3.1;
Figure S1). No differences could be observed between indi-
viduals with inherited variants versus DNMs in KMT2A
when compared to cohort versus DNM in that gene
(Figure 2C).
Supervised Naive Bayes Models Have Diagnostic
Potential
We then wished to determine whether naive Bayes
models16 could be used to establish patterns in the quanti-938 The American Journal of Human Genetics 105, 933–946, Novemtative data that would constitute diagnostically useful
in silico syndromes. This analysis was performed without
using the associated HPO terms. There were 24 genes (a to-
tal of 377 probands) in which R10 individuals had
reported DNM and sufficiently complete growth and
developmental milestone data were available. These
models were built using ten features, including the four
growth and four development measurements described
above, plus gender and gestation (Figure 2D, probability
tables in Data S1). Each feature was ‘‘discretized’’ (high,
middle and low, or high and low groups for continuous
features; male and female for sex) as described in Material
and Methods.
Each supervised naive Bayes gene-phenotype model was
defined independently. No attempt was made to derive
models that would distinguish one DNM from another.
That said, the performance of the classification models
on the training set resulted in 123/377 (32.6%) correct
predictions of gene class (Figure 2E) compared to 4%
(1/24) expected by chance. This type of analysis can
underestimate the true error rate of a classifier, so we also
used 0.632 bootstrap method employing resampling
with replacement and testing on samples not used in
training,12 which suggested a classification accuracy of
20.1%. The NSD1, DYRK1A, and TCF20 models each had
accuracies >30%. KAT6B, DYNC1H1, ADNP, KCNQ2, and
SCN2A were poorly predicted with accuracies <10%.
Unsupervised Naive Bayes Models
We then applied an unsupervised naive Bayes classifier to
the first 6,993 DDD probands with adequate data (see
Figure 1C) resulting in 23 classes, which we have termed
in silico syndromes. These ISS (Figure 3A, probability ta-
bles in Data S1) contained between 49 and 1,049 probands
(median 219). Mapping ISSBayes:1-23 onto tSNE cluster
graphs17 resulted in visually apparent patterns for growth
(Figure 3B) and to a lesser extent for development
(Figure S2). It is apparent that seven ISSs have similar pre-
dominantly high values for growth but are distinguished
by differing combinations of developmental attributes
(illustrated by clustering the table, Data S2). Low values
for growth features are shared by six ISSs and again these
patterns are distinguished by developmental characteris-
tics. 13 of the 23 ISSs have a predominant gender. To quan-
tify the extent to which the ISS classes can be recovered
from the data, the proband to ISS labels can be assumed
to be correct and the classification error estimated as above
for supervised naive Bayes classification by 0.632 boot-
strapping. The proposed ISS labels are obtained with an er-
ror of 5.6%, giving an accuracy of 94.4% which lends
weight to the phenotypic distinctions they make.
Given that HPO terms were not used to generate the ISSs,
we reasoned that HPO term similarity between probands
within a ISS may be a reasonable test of validity. HPO sim-
ilarity scores were significantly higher than expected in 13/
23 ISSBayes (Table 3, p values computed by the method of
Akawi and McRae15). To enrich for terms that would beber 7, 2019
Table 2. Clinical and Genetic Features of Individuals with Apparently Inherited, High Impact Variants in ANKRD11
Proband ID 265784 258544 276420 279343 301622 303467 305225
NC_000016.9
Genomic Variant
g.89334964_
89334970dup
g.89350555del g.89350831del g.89349780_89349781del g.89351044_
89351045del
g.89346281del g.89348863G>A
NM_013275.5 cDNA c.7909_7915dup c.2397del c.2119del c.3170_3171del c.1908_1909del c.6670del c.4087C>T
NP_037407.4 Protein p.Leu2639GlnfsTer113 p.Glu800LysfsTer63 p.Glu707LysfsTer12 p.Lys1057ArgfsTer10 p.His636GlnfsTer26 p.Glu2224ArgfsTer113 p.Arg1363Ter
Inheritance uncertain (subsequently
confirmed de novo)
uncertain (subsequently
confirmed de novo)
maternal maternal maternal paternal paternal
Child/parental VAF 4/4:? 9/5:? 20/20:23/23 32/36:31/49 26/28:26/24 13/10:6/13 35/36:41/46
Consequence frameshift variant frameshift variant frameshift variant frameshift variant frameshift variant frameshift variant stop gained
Birth weight 1.23 0.08 0.54 1.29 1.66 0.32 0.16
Height 2.39 1.87 0.76 2.92 2.06 2.37 4.02
Weight 2.49 0.5 0.41 3.58 1.45 0.52 2.97
OFC 2.38 0.74 2.48 4.78 3.35 2.83 2.64
HPO terms (not
used in similarity
analysis)
Abnormal facial shape;
Intellectual disability;
mild; Microcephaly;
Short stature
2-3 toe syndactyly;
Abnormal facial shape;
Abnormality of dental
morphology; Avascular
necrosis of the capital
femoral epiphysis;
Broad finger;
Clinodactyly of
the 5th finger;
Cryptorchidism; Global
developmental delay;
High palate; Short neck;
Strabismus
Anteverted nares; Behavioral
abnormality; Global
developmental delay;
Hirsutism; Hypermetropia;
Protruding ear; Sensorineural
hearing impairment; Short
attention span; Synophrys;
Wide mouth
Brachycephaly;
Clinodactyly of the
5th finger; Conductive
hearing impairment;
Global developmental
delay; Prominent
metopic ridge; Short
stature; Sparse scalp hair
Fetal fifth finger
clinodactyly;
Moderate global
developmental
delay; Short stature
Delayed speech and
language development;
Edema of the dorsum
of feet; Feeding
difficulties; Fine hair;
Immunologic
hypersensitivity;
Infra-orbital crease;
Moderate global
developmental delay;
Neonatal hypotonia;
Short foot; Thin upper
lip vermilion;
Upslanted palpebral
fissure
2-3 toe syndactyly;
Failure to thrive in
infancy; Frontal
bossing; Long
eyelashes; Moderate
global developmental
delay; Sacral dimple;
Short stature
Family history none none father has intellectual
disability (variant maternally
inherited)
father has mild KBG
on clinical reassessment
none none none
Clinically confirmed yes yes yes yes possible yes yes
Notes DNM in SOX10 not
classified
referred with a clinical
diagnosis of KBG
also has KMT6A in-frame
dup (mat) amd TECTA
nonsense mutation (pat)
both unclassified
ACAN variant reported
(likely benign)
missense in TRIP12
reported (likely
benign)
TSC2 variant reported
(unclassified)
no variants reported
Abbreviations: VAF, variant allele frequency; DNM, de novo mutation; OFC, occipito-frontal circumference.
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Figure 3. Phenotypic Prototypes and Predictions from Naive Bayes Models
Unsupervised naive Bayes clustering of the 6,993 DDD probands into 23 distinct classes, here termed in silico syndromes (ISSBayes).
(A) A graphical representation of the phenotypic characteristics that define each ISSBayes using 10 discretized phenotypic values, a key is
provided for each of the color-coded groups.
(B) Scatterplots show the projection into two dimensions by t-SNE of growth for each ISSBayes where symbols are color coded by ISS.
(C) To determine whether the ISSBayes showed any agreement with DNM in 24 different genes, we created a confusion matrix which did
not indicate strong evidence of concordance of the phenotypic and genetic assignments.
(D) We also defined eight sets of HPO terms that describe site-specific malformations looked for over-representation of probands when
categorized by profile (Fisher’s exact test). Three malformation types were enriched in nine different profiles (p value adjusted for testing
23 profiles, adjusted p% 0.05 considered significant).unambiguously assigned, we created eight subsets for or-
gan-specific malformations (respiratory, GI_abdominal,
cardiovascular, limb, face_ear, brain, eye, genitourinary).
Of these only brain, limb, and face_ear showed evidence
for enrichment in 6, 1, and 2 different, non-overlapping
ISSs, respectively (Figure 3D).
Estimating the Potential for Phenotype First Approaches
to Gene Discovery
We defined a set of strictly filtered variant calls from the
proband exome data. A minor allele frequency of
<0.0001 in ExAC, EVS, and 1KG data was used. Any vari-
ants with an internal (DDD) variant count of >3 were
excluded to minimize the risk of technical artifact. Likely
gene disruptive variants were included in genes that
showed significant intolerance of such variants at a popu-
lation level (ExAC pLi > 0.5). Missense variants with
CADD score > 30 were included in genes with evidence
of missense constraint in human populations (z score >
3 from ExAC). This resulted in a total of 12,458 variants
in 6,993 probands (5,858 variant positive probands,
3,617 genes). We then looked for indicative enrichment
of genes within the 23 ISSBayes using a subset of genes in940 The American Journal of Human Genetics 105, 933–946, Novemwhich variants were identified in at least 8 probands
(359/3,617 genes). No gene achieved genome-wide signif-
icance. 11/359 genes (SMC1A, WDR45, CHD6, ASXL3,
SPTBN2, ABCE1, CACNA1D, HECW2, HNRNPU, BCL9,
PTPRU) were enriched above a nominal level (Figures 4A
and 4B; Table 4). ASXL3 was the most enriched gene
(ISS:6 and ISS:10). 6/11 of these genes (SMC1A, ASXL3,
CACNA1D, HECW2, HNRNPU, WDR45) had been previ-
ously coded as genes in which variants are known to cause
developmental disease in the G2P database18 constituting
an odds ratio of 2.55 (p ¼ 0.11 by Fischer’s test considering
the 359 genes with sufficient numbers of probands to be
tested as the background set which was itself enriched for
genes containing disease-associated variants).
On clinical review of the individuals with variants in five
genes that were not in G2P, only those with variants in
SPTBN2 were plausibly diagnostic (Table 5). Mutations in
SPTBN2 have been identified in an adult-onset, auto-
somal-dominant spinocerebellar ataxia 5 (SCA5 [MIM:
600224]).19 Infantile-onset ataxia and global develop-
mental delay has been reported with biallelic mutations
in SPTBN2 (SCA14 [MIM: 615386]). De novo monoallelic
variants resulting in p.Arg480Trp have been reported inber 7, 2019
Table 3. HPO Term Enrichment in the 23 ISSBayes Derived from
Unsupervised Naive Bayes Classification
ISSBayes p Value ISSBayes p Value
ISS-1 0.999 ISS-13 0.079
ISS-2 0.007* ISS-14 0.009*
ISS-3 0.001* ISS-15 0.085
ISS-4 0.028* ISS-16 0.003*
ISS-5 0.999 ISS-17 0.001*
ISS-6 0.001* ISS-18 0.375
ISS-7 0.001* ISS-19 0.001*
ISS-8 0.999 ISS-20 0.005*
ISS-9 0.607 ISS-21 0.376
ISS-10 0.001* ISS-22 0.001*
ISS-11 0.870 ISS-23 0.091
ISS-12 0.035* – –
Asterisk (*) indicates significant p values (%0.05).three individuals in separate case reports with infantile-
onset ataxia and global developmental delay.20–22 Three
DDD individuals have de novomissense variants in SPTBN2
(Figure 4D), two of which are predicted to result in the
p.Arg480Trp substitution (NB: one is the same individual
as Parolin Schnekenberg et al.20). The other de novo variant
has the consequence p.Ile165Leu. This amino acid
substitution is located in the region between CH1 and
CH2 domains of SPTBN2, very close to a likely pathogenic
de novo variant (GenBank: NM_006946.3 (SPTBN2):
c.470T>C [p.Ile157Thr]) reported in ClinVar. Moreover,
it is interesting to note that two previously reported
missense variants also occur at the CH1:CH2 interface
(Figure 4C): p.Leu253Pro associated with adult-onset19
and p.His278Arg associated with childhood-onset23
SCA5. It was shown that p.Leu253Pro is damaging because
it disrupts the interaction between the two CH domains,
which increases actin-binding affinity of SPTBN2.24 It is
likely that a similar mechanism underlies the other three
mutations at the CH1:CH2 interface, and we can speculate
that the degree of disruption may explain the variation in
age of onset.Discussion
There is a pressing need to develop statistically robust and
scaleable methods to incorporate phenotypic data into
the analytical pipelines in both diagnostic and clinical
research genomics. Statistical approaches to WES/WGS
analysis in human disease cohorts have proven to be
extremely powerful in identifying new disease associations
with individual genes and to identify causative mutations
in known genes. This has been particularly true using fam-
ily-based study designs in developmental disorders due to
the very high frequency of causative de novo mutationsThe American(DNMs). There is, however, a 20% (or greater) false posi-
tive rate estimated for plausibly deleterious DNMs in genes
containing disease-associated variants.9 The difficulty in
interpreting the clinical significance of ultra-rare variants
becomes significantly greater where the proband is
sequenced on their own or with only one parent. The
phenotype of the affected individual represents accessible
and independent data which can be used to rank the vari-
ants identified using human genetic analysis alone. We
found it surprisingly difficult to estimate an expected level
of improvement in clinical utility before starting this
study. Many published diagnostic criteria for individual
mendelian disorders include growth and developmental
milestone data as key components of the decision tree
(e.g., Cornelia de Lange syndrome25), but we could not
identify studies that had assessed the additional clinical
utility of such information.
Computational use of structured, categorical, medical
terminology—such as the Human Phenotype Ontology
(HPO)26—is now in widespread use in clinical
research.27–31 The primary aim of this paper has been to
assess the diagnostic utility of systematically collected
quantitative data (derived from growth and development
of the affected individuals) in affected individuals who
were recruited to the DDD study with severe/extreme
developmental disorders. Such data could be used alone
or in combination with existing similarity measures that
use HPO terms. Growth has major advantages as a pheno-
type for computational use; it is quantitative, multi-modal
(height, weight, head circumference), routinely docu-
mented in pediatric health records, and can be normalized
by age using z-scores. Birth weight and gestation can be
used as a proxy for prenatal growth. Proportionate or
disproportional growth anomalies are common in devel-
opmental disorders32–34 and growth parameters are
commonly used in diagnostic criteria for individual syn-
dromes.35 The diagnostic use of developmental milestones
have received little attention to date. Although these data
are quantitative, the measurements are in temporal inter-
vals and are not normally distributed, meaning it is not
possible to produce age- and sex-normalized z-scores. It is
also true that the developmental milestones are not re-
corded routinely in many electronic medical records and
that parental recall, for example of the precise age at sitting
unaided, is of uncertain accuracy. In spite of these limita-
tions, developmental milestone data are multimodal and
have obvious potential in the diagnosis of developmental
disorder.
Our aim was to utilize the breadth of phenotypic data—
HPO terms, growth, and developmental milestones—that
was collected systematically on recruitment to the DDD
study. An early exploratory analysis, which combined
tSNE with nearest neighbor approaches (Figure S3),
showed only modest evidence of clustering by genetic
diagnosis and it was not possible for us to use this
approach to create gene-specific models to apply to indi-
vidual genomic analyses. In contrast, we found improvedJournal of Human Genetics 105, 933–946, November 7, 2019 941
Figure 4. Discovery of Candidate Diagnostic Genes by Phenotypic Profile
(A) Heatmap of ISSBayes 1:23 tested for over-representation of genes passing the variant filtering in the phenotypic profiles (Fisher’s exact
test, p value adjusted for testing 23 profiles, adjusted p% 0.05 considered significant, 359 genes had at least 8 probands; mean 1.36 SNV
per proband). The variants were derived from probandwhole-exome sequencing in the 8k data freeze were filtered byMAF, consequence,
pLi, CADD, andNSV scores to produce a set of 12,458 plausible diagnostic SNVs, mean 2.12 per proband in a set of 6,993 probands. Gene
names in black are known developmental genes in the G2P database, those in blue are not in the G2P database.
(B) A Manhattan plot shows the p values of enriched genes.
(C) Pathogenic mutations at the CH1:CH2 interdomain interface of SPTBN2. The site of the novel DDD mutation identified here is
shown in red, while the sites of the previously identified pathogenic mutations are shown in orange. The crystal structure of alpha-ac-
tinin (PDB: 4D1E) was used to build a homology model of SPTBN2 using SWISS-MODEL. The cryoelectron microscopy structure of the
SPTBN2 CH1 domain (PDB: 6ANU) was very similar to the model (RMSD ¼ 1.5 A˚).
(D) A cartoon of SPTBN2 protein structure. The distribution of pathogenic and likely pathogenic variants recorded in ClinVar is indicated
by the yellow (missense) and red (nonsense and frameshift) triangles above the protein. The color of the variant text indicates the age of
onset of the ataxia as defined by the key. The dashed line red boxes indicate the position of the de novo variants identified within the
DDD cohort.clustering by ISS groupings. We then assessed the utility of
median Euclidean distances as a method of determining
how similar the patterns of z-scores for quantitative phe-
notypes are among genetically defined sets of probands.
mEuD provides a computationally and conceptually sim-
ple method of determining which measured feature in a
group of individuals with comparable genotypes in a spe-
cific gene may be of discriminative value. Individuals
with plausibly causative DNM in MED13L show evidence
for similarity in growth and HPO term usage but not for
developmental milestones (Table 1). This phenomenon
means that mEuD models can be tailored to an individual
locus and genotype allowing us to identify causative vari-
ants in ANKRD11 that have been inherited from appar-
ently unaffected parents. In 6 out of 7 cases, the Euclidean
distance between these probands and the 32 DNM case
subjects is less than expected by chance (p < 0.05 using942 The American Journal of Human Genetics 105, 933–946, NovemHPO terms; Figure S1). mEuD models may improve diag-
nostic interpretation in proband-only analysis by aug-
menting the standard genetic approaches to prioritizing
variants with a phenotypic match.
Naive Bayes classification allowed us to generate gene-
phenotypeprofiles (or in silico syndromes [ISSs])with signif-
icant diagnostic potential. Although these models are not
very discriminative when used alone, in conjunction with
independent phenotype data such as HPO terms and facial
image-derived measurements,36 the naive Bayes ISS could
be of use in clinical diagnostic practice. It is now important
to develop statistically robust approaches to integration of
such data to allow the combined models to be tested in
well-characterized cohorts to determine their impact on
precision and recall of confirmed molecular diagnoses.
We used naive Bayes classification-derived ISSs to test
whether a quantitative phenotype-driven approach couldber 7, 2019
Table 4. Clinical Summary of Genes Showing Nominal Enrichment in ISSBayes
Gene ISS DDG2P
Total Number
of Filtered
Variants
Variants in Enriched ISS Variants Not Enriched in ISS
Obvious Clinical
Similarity?Total LoF NSV
DDD Reports
Same Variant
DDD Reports
Different Gene Total LoF NSV
DDD Reports
Same Variant
DDD Reports
Different Gene
ABCE1 19 no 9 5 3 2 NA 3 4 4 0 NA 1 no
ASXL3 6 monoallelic:loss of function 26 5 5 0 5 0 21 21 0 14 1
BCL9 21 no 10 3 3 0 NA 1 7 7 0 NA 3 no
CACNA1D 17 monoallelic:activating AND
biallelic:loss of function
16 4 2 2 0 1 12 2 10 2 2
CHD6 23 no 19 4 0 4 NA 1 15 1 14 NA 3 no
HECW2 10 monoallelic:all missense/
in-frame
14 4 1 3 0 0 10 2 8 0 2
HNRNPU 3 monoallelic:loss of function 9 3 3 0 3 0 6 6 0 4 0
PTPRU 13 no 16 5 1 4 NA 1 11 0 11 NA 2 no
SMC1A 19 X-linked dominant:all
missense/in-frame AND
X-linked dominant:loss of
function
9 6 6 0 5 0 3 2 1 3 0
SPTBN2 17 no 25 5 0 5 NA 0 20 1 19 NA 5 yes
WDR45 17 X-linked dominant:loss
of function
9 3 3 0 2 0 6 6 0 6 0
Total 162 47 27 20 15 6 115 52 63 23 25
Abbreviations: LoF, loss-of-function variants; NSV, non-synonymous (missense) variants; ISSs, in silico syndromes.
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Table 5. Clinical and Genetic Feature Recorded for Individuals with De Novo Mutations in SPTBN2
DECIPHER ID 261578 282590 274803
NC_000011.9 genomic variant g.66475202G>A g.66475202G>A g.66481869T>G
NM_006946.3 cDNA c.1438C>T c.1438C>T c.493A>C
NP_008877.1 protein p.Arg480Trp p.Arg480Trp p.Ile165Leu
Inheritance de novo de novo de novo
Mother’s age 23 33 37
Father’s age 25 36 38
Birthweight Z score 0.97 1.13 0.91
Height Z score – 0.78 1.23
Weight Z score – 0.15 1.75
OFC Z score 1.75 1.57 0.5
HPO terms frontal upsweep of hair;
global developmental
delay; high forehead;
hypopigmentation of hair;
tremor
abnormal motor neuron
morphology; cerebellar
atrophy; intellectual
disability; mild
ataxia; cerebral atrophy;
dysmetria; global
developmental delay;
hypertonia; motor delay;
strabismus; truncal ataxia
Notes no other causative
variants identified
no other causative variants
identified
no other causative variants
identifiedbe used for gene discovery in developmental disorders. We
derived 23 different ISSs from 6,993 probands in DDD.
Nominal evidence for enrichment of likely deleterious
mutations was found in 11 different genes in 8/23 ISSs.
6/11 genes were known monoallelic DD loci, including
two X-linked genes. Of the 5 remaining genes, one
(SPTBN2) has convincing evidence that it is indeed a
monoallelic DD gene, probably acting via a dominant-
negative mode of action.
The collection and reproducibility of phenotypic data
collection in genetic studies needs to achieve the same
status as the sequence data. This requires rigorous and
consistent standards to enable the data to be used and
replicated computationally within and between studies.
The accurate definition of aggregate phenotypic patterns
in individuals with comparable genotypes has use beyond
clinical diagnostics as it may provide biological insights via
the identification of modular functions. At present, quan-
titative phenotypic data cannot produce causative geno-
type-disease models with strong discriminative value for
many conditions. This may be due to the relatively small
numbers of affected individuals in each group but it
is equally plausible that many conditions may be genu-
inely indistinguishable. However, it seems likely that
quantitative data used in combination with other pheno-
typic information (clinical terms, facial image analysis,
etc.) will have significant utility in ranking variants that
have survived the basic filtering using technical, conse-
quence, and population frequency parameters. Relatively
simple modifications to electronic health systems should
enable the extraction of data in computational tractable
formats. Systematic collection, storage, and retrieval
should improve both the completeness and accuracy of944 The American Journal of Human Genetics 105, 933–946, Novemthe data available for diagnostic analysis in individuals
with developmental disorders. We challenge authors and
publishers to ensure that all phenotypic data—quantita-
tive and categorical—associated with human genetic dis-
ease are accessible using consistent formats that maximize
the potential for future meta-analysis.Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
1016/j.ajhg.2019.09.015.Acknowledgments
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